{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "3963089",
  "DateCompleted": {
    "Year": "1986",
    "Month": "05",
    "Day": "22"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "06",
    "Day": "15"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0002-9378",
      "JournalIssue": {
        "Volume": "154",
        "Issue": "4",
        "PubDate": {
          "Year": "1986",
          "Month": "Apr"
        }
      },
      "Title": "American journal of obstetrics and gynecology",
      "ISOAbbreviation": "Am J Obstet Gynecol"
    },
    "ArticleTitle": "Lactation suppression and puerperal fever.",
    "Pagination": {
      "StartPage": "940",
      "EndPage": "941",
      "MedlinePgn": "940-1"
    },
    "Abstract": {
      "AbstractText": [
        "Seventy-five puerperal women who did not wish to breast-feed were treated with bromocriptine mesylate (Parlodel) or placebo in a prospective, randomized, double-blind study. Results revealed a puerperal fever incidence of 18.6%, 13.3% of which was due to breast engorgement and 5.3% to an infectious process. Parlodel prevented puerperal fever in 87.9% of patients. If Parlodel was given within 18 hours of delivery, physiologic puerperal fever was prevented in 100% of cases."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Almeida",
        "ForeName": "O D",
        "Initials": "OD",
        "Suffix": "Jr"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kitay",
        "ForeName": "D Z",
        "Initials": "DZ"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Comparative Study",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Am J Obstet Gynecol",
    "NlmUniqueID": "0370476",
    "ISSNLinking": "0002-9378"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "3A64E3G5ZO",
      "NameOfSubstance": "Bromocriptine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Bromocriptine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Depression, Chemical"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Evaluation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "etiology",
        "prevention & control"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Lactation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pregnancy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prospective Studies"
    },
    {
      "QualifierName": [
        "etiology",
        "prevention & control"
      ],
      "DescriptorName": "Puerperal Disorders"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Random Allocation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    }
  ]
}